KAEF Stock Overview
PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia.
Kimia Farma (Persero) Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||Rp1,465.00|
|52 Week High||Rp3,670.00|
|52 Week Low||Rp1,375.00|
|1 Month Change||-1.01%|
|3 Month Change||-32.49%|
|1 Year Change||-39.46%|
|3 Year Change||-56.79%|
|5 Year Change||-48.23%|
|Change since IPO||597.62%|
Recent News & Updates
|KAEF||ID Pharmaceuticals||ID Market|
Return vs Industry: KAEF underperformed the ID Pharmaceuticals industry which returned 1.9% over the past year.
Return vs Market: KAEF underperformed the ID Market which returned 17.3% over the past year.
|KAEF Average Weekly Movement||6.2%|
|Pharmaceuticals Industry Average Movement||3.7%|
|Market Average Movement||6.2%|
|10% most volatile stocks in ID Market||12.0%|
|10% least volatile stocks in ID Market||2.9%|
Stable Share Price: KAEF is not significantly more volatile than the rest of ID stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: KAEF's weekly volatility (6%) has been stable over the past year.
About the Company
PT Kimia Farma (Persero) Tbk produces and sells medicines, herbal medicines, iodine, salts, quinine and their derivative products, and vegetable oils in Indonesia. The company operates through Manufacturing, Distribution, Retail, and Other Services segments. It also manufactures and sells generic, ethical, license and narcotic medicines, and over the counter medicines, health equipment, raw materials, medicines, medical devices, and cosmetics.
Kimia Farma (Persero) Fundamentals Summary
|KAEF fundamental statistics|
Is KAEF overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|KAEF income statement (TTM)|
|Cost of Revenue||Rp8.81t|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
|Earnings per share (EPS)||54.42|
|Net Profit Margin||2.35%|
How did KAEF perform over the long term?See historical performance and comparison
0.09%Current Dividend Yield
Is Kimia Farma (Persero) undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: KAEF (IDR1465) is trading above our estimate of fair value (IDR10.98)
Significantly Below Fair Value: KAEF is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: KAEF is poor value based on its Price-To-Earnings Ratio (26.9x) compared to the ID Pharmaceuticals industry average (20.7x).
PE vs Market: KAEF is poor value based on its Price-To-Earnings Ratio (26.9x) compared to the ID market (18.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate KAEF's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: KAEF is good value based on its Price-To-Book Ratio (1.1x) compared to the ID Pharmaceuticals industry average (2.5x).
How is Kimia Farma (Persero) forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Kimia Farma (Persero) has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Kimia Farma (Persero) performed over the past 5 years?
Past Performance Score4/6
Past Performance Score 4/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: KAEF has high quality earnings.
Growing Profit Margin: KAEF's current net profit margins (2.4%) are higher than last year (0.2%).
Past Earnings Growth Analysis
Earnings Trend: KAEF's earnings have declined by 24.3% per year over the past 5 years.
Accelerating Growth: KAEF's earnings growth over the past year (1613.7%) exceeds its 5-year average (-24.3% per year).
Earnings vs Industry: KAEF earnings growth over the past year (1613.7%) exceeded the Pharmaceuticals industry 11.7%.
Return on Equity
High ROE: KAEF's Return on Equity (4%) is considered low.
How is Kimia Farma (Persero)'s financial position?
Financial Health Score2/6
Financial Health Score 2/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: KAEF's short term assets (IDR6,303.5B) exceed its short term liabilities (IDR5,980.2B).
Long Term Liabilities: KAEF's short term assets (IDR6,303.5B) exceed its long term liabilities (IDR4,548.1B).
Debt to Equity History and Analysis
Debt Level: KAEF's net debt to equity ratio (99.6%) is considered high.
Reducing Debt: KAEF's debt to equity ratio has increased from 36.1% to 110% over the past 5 years.
Debt Coverage: KAEF's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: KAEF's interest payments on its debt are not well covered by EBIT (1.7x coverage).
What is Kimia Farma (Persero) current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: KAEF's dividend (0.086%) isn’t notable compared to the bottom 25% of dividend payers in the ID market (1.14%).
High Dividend: KAEF's dividend (0.086%) is low compared to the top 25% of dividend payers in the ID market (4.14%).
Stability and Growth of Payments
Stable Dividend: KAEF is not paying a notable dividend for the ID market, therefore no need to check if payments are stable.
Growing Dividend: KAEF is not paying a notable dividend for the ID market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: KAEF is not paying a notable dividend for the ID market.
Cash Payout to Shareholders
Cash Flow Coverage: KAEF is paying a dividend but the company has no free cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Verdi Budidarmo (52 yo)
Dr. Verdi Budidarmo, Apt serves as President Director at PT Kimia Farma (Persero) Tbk since September 18, 2019. He served as President Commissioner at PT Phapros Tbk since August 26, 2019 until 2021. He ha...
Experienced Management: KAEF's management team is considered experienced (3 years average tenure).
Experienced Board: KAEF's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
PT Kimia Farma (Persero) Tbk's employee growth, exchange listings and data sources
- Name: PT Kimia Farma (Persero) Tbk
- Ticker: KAEF
- Exchange: IDX
- Founded: 1817
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: Rp8.137t
- Shares outstanding: 5.55b
- Website: https://kimiafarma.co.id
Number of Employees
- PT Kimia Farma (Persero) Tbk
- Jl. Veteran No.9
- Jakarta Raya
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/24 00:00|
|End of Day Share Price||2022/05/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.